LSE · ABDX.L
Abingdon Health Plc
£0.09-£0.01 (-5.56%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 34.62% below the high.
Loading market information…
NASDAQ · AKU · USD
Stock price, earnings
Quote as of Oct 25, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Akumin Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Akumin Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Akumin Inc. specializes in delivering outpatient diagnostic imaging solutions across the United States. Its operations are divided into two main divisions: Radiology and Oncology. Through a network of roughly 200 imaging centers, which it either owns or manages, Akumin delivers a wide array of medical imaging modalities. These include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and various other diagnostic or interventional radiology procedures. The company extends its outpatient radiology and oncology services and comprehensive solutions to approximately 1,000 hospitals and healthcare systems spanning 46 states. Established in 2015, Akumin Inc. maintains its corporate headquarters in Plantation, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.09-£0.01 (-5.56%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 34.62% below the high.
$3.75+$0.01 (+0.27%)
PharmChem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.78% below the high.
$0.17-$0.01 (-7.78%)
MDxHealth S.A.’s quoted price sits in the lower half of its reported 52-week range, 96.64% below the high.
$0.61+$0.61 (+100.0%)
23andMe Holding Co.’s quoted price sits in the lower half of its reported 52-week range, 95.25% below the high.
$0.33+$0.33 (+100.0%)
Centogene N.V.’s quoted price sits in the lower half of its reported 52-week range, 24.24% below the high.
$0.02-$0.01 (-35.59%)
Invitae Corporation’s quoted price sits in the lower half of its reported 52-week range, 99.19% below the high.
$0.02$0.00 (0.0%)
LumiraDx Limited’s quoted price sits in the lower half of its reported 52-week range, 43.26% below the high.
£0.00£0.00 (0.0%)
Verici Dx plc’s quoted price sits in the lower half of its reported 52-week range, 78.04% below the high.
